Should I buy or sell Centessa Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNTA shares. View CNTA analyst ratings or view top-rated stocks .

What is Centessa Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Centessa Pharmaceuticals' stock. Their CNTA share price targets range from $5.00 to $15.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests that the stock has a possible downside of 7.2%. View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts .

How have CNTA shares performed in 2024?

Centessa Pharmaceuticals' stock was trading at $7.96 at the start of the year. Since then, CNTA stock has increased by 35.4% and is now trading at $10.78. View the best growth stocks for 2024 here .

Are investors shorting Centessa Pharmaceuticals?

Centessa Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,740,000 shares, an increase of 13.0% from the March 15th total of 1,540,000 shares. Based on an average trading volume of 392,100 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.1% of the company's stock are short sold. View Centessa Pharmaceuticals' Short Interest .

When is Centessa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CNTA earnings forecast .

How were Centessa Pharmaceuticals' earnings last quarter?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.10.

When did Centessa Pharmaceuticals IPO?

Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free CNTA Stock Alerts

$10.80

+0.02 (+0.19%)

(As of 11:38 AM ET)

Compare

Today's Range: $10.37
▼
$10.80
50-Day Range: $7.46
▼
$12.20
52-Week Range: $3.96
▼
$12.45

Volume: 14,820 shs
Average Volume: 355,423 shs
Market Capitalization: $1.08 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Centessa Pharmaceuticals alerts:

Centessa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 7.2% Downside
$10.00 Price Target
Short Interest: Bearish
3.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 4 Articles This Week
Insider Trading: Selling Shares
$642,344 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.83) to ($1.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.64 out of 5 stars

Medical Sector

859th out of 913 stocks

Pharmaceutical Preparations Industry

403rd out of 427 stocks

1.4

Analyst's Opinion

Consensus Rating
Centessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Centessa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.08% of the float of Centessa Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Centessa Pharmaceuticals has recently increased by 12.99%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Centessa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Centessa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CNTA.

2.6

News and Social Media Coverage

News Sentiment
Centessa Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Centessa Pharmaceuticals this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 10 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $642,344.00 in company stock.
Percentage Held by Insiders
11.54% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.83) to ($1.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Centessa Pharmaceuticals is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Centessa Pharmaceuticals is -6.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Centessa Pharmaceuticals has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

Click here to learn more while there’s still time.

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

CNTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNTA Stock News Headlines

March 27, 2024 | insidertrades.com

Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 51,160 Shares of Stock

April 14, 2024 | americanbankingnews.com

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.3%

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Centessa Pharmaceuticals Amid Promising ORX750 Prospects and Favorable Trial Results

March 29, 2024 | msn.com

CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023

March 28, 2024 | finanznachrichten.de

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

March 28, 2024 | finance.yahoo.com

Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results

March 28, 2024 | globenewswire.com

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”

March 27, 2024 | finance.yahoo.com

Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares

March 26, 2024 | finance.yahoo.com

7 Biotech Stocks Ready to Ride the Sector’s Resurgence

March 20, 2024 | wsj.com

Centessa Pharmaceuticals PLC ADR

March 19, 2024 | investing.com

Centessa Pharmaceuticals PLC ADR (CNTA)

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 16, 2024 | finance.yahoo.com

CNTA Apr 2024 7.500 put

March 16, 2024 | finance.yahoo.com

CNTA Apr 2024 5.000 call

March 16, 2024 | finance.yahoo.com

CNTA Jul 2024 7.500 put

March 12, 2024 | finance.yahoo.com

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

March 7, 2024 | markets.businessinsider.com

Upgraded Buy Rating and Price Target for Centessa Pharmaceuticals on SerpinPC’s Market Potential

February 22, 2024 | finance.yahoo.com

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

February 15, 2024 | seekingalpha.com

CNTA Centessa Pharmaceuticals plc

February 14, 2024 | benzinga.com

Centessa Pharmaceuticals Stock (NASDAQ:CNTA) Dividends: History, Yield and Dates

February 10, 2024 | markets.businessinsider.com

Centessa Pharmaceuticals Unveils Clinical Data Online

February 9, 2024 | finance.yahoo.com

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

February 5, 2024 | seekingalpha.com

Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential

February 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Centessa Pharmaceuticals on Strong R&D Prospects and Market Potential

December 27, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics

See More Headlines

Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNTA
CUSIP: N/A
CIK: 1847903
Web: www.centessa.com
Phone: 44-73-9178-9784
Fax: N/A
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $15.00
Low Stock Price Target: $5.00
Potential Upside/Downside: -7.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-151,090,000.00
Net Margins: N/A
Pretax Margin: -2,570.28%
Return on Equity: -56.72%
Return on Assets: -39.39%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 8.00
Quick Ratio: 8.00

Sales & Book Value

Annual Sales: $6.85 million
Price / Sales: 157.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.42 per share
Price / Book: 4.45

Miscellaneous

Outstanding Shares: 100,306,000
Free Float: 88,731,000
Market Cap: $1.08 billion
Optionable: Optionable
Beta: 1.38

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Saurabh Saha M.D. (Age 48)
Ph.D., CEO & Director
Comp: $957.67k
Dr. Gregory M. Weinhoff M.B.A. (Age 53)
M.D., Principal Accounting Officer & CFO
Comp: $655k
Dr. David M. Chao Ph.D. (Age 56)
Chief Administrative Officer
Comp: $655k
Ms. Tia L. Bush (Age 53)
Chief Technology & Quality Officer
Ms. Kristen K. Sheppard Esq.
J.D., Senior Vice President of Investor Relations & Corporate Communications
Mr. Iqbal J. Hussain L.L.B. (Age 43)
General Counsel, Chief Compliance Officer & Corporate Secretary
Ms. Karen M. Anderson (Age 56)
Chief People Officer
Dr. Antoine Yver M.D. (Age 66)
M.Sc., Executive VP & Chairman of Development
Comp: $449.58k
Dr. Harris L. Rotman Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Patrick Yue M.D.
Senior VP of Clinical Development & Innovative Medicines

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Centessa Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNTA shares.
View CNTA analyst ratings or view top-rated stocks.
What is Centessa Pharmaceuticals' stock price target for 2024?: 7 Wall Street research analysts have issued 12 month price targets for Centessa Pharmaceuticals' stock. Their CNTA share price targets range from $5.00 to $15.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests that the stock has a possible downside of 7.2%.
View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts.
How have CNTA shares performed in 2024?: Centessa Pharmaceuticals' stock was trading at $7.96 at the start of the year. Since then, CNTA stock has increased by 35.4% and is now trading at $10.78.
View the best growth stocks for 2024 here.
Are investors shorting Centessa Pharmaceuticals?: Centessa Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,740,000 shares, an increase of 13.0% from the March 15th total of 1,540,000 shares. Based on an average trading volume of 392,100 shares, the days-to-cover ratio is presently 4.4 days. Currently, 3.1% of the company's stock are short sold.
View Centessa Pharmaceuticals' Short Interest.

When is Centessa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CNTA earnings forecast.
How were Centessa Pharmaceuticals' earnings last quarter?: Centessa Pharmaceuticals plc (NASDAQ:CNTA) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.10.
When did Centessa Pharmaceuticals IPO?: Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.
How do I buy shares of Centessa Pharmaceuticals?: Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

CNTA Stock Price History

CNTA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CNTA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™